Recent Updates
Recently added Catalysts

xanomeline

Phase 3

Schizophrenia | Small molecule | Psychiatry |Bristol-Myers Squibb Company|Last Updated: May 5, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMCBiomarker
Total Trials9
Total Enrollment2,356
FDA Designations
No designations recorded
Clinical Trials (9)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05919823A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaPHASE3 COMPLETED 202May 29, 2023Dec 9, 2024Dec 17, 202528 China
NCT05304767An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPHASE3 RECRUITING 280Mar 7, 2022Mar 19, 2026Mar 11, 2026175 United States, Bulgaria +7
NCT05145413A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPHASE3 COMPLETED 396Nov 12, 2021Mar 19, 2025May 5, 2026166 United States, Bulgaria +6
NCT04820309An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)PHASE3 COMPLETED 566Jun 2, 2021May 24, 2024Sep 17, 2025117 United States, Puerto Rico
NCT04738123A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)PHASE3 COMPLETED 256Apr 6, 2021Dec 7, 2022Dec 9, 202432 United States, Ukraine
NCT04659174An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)PHASE3 COMPLETED 152Feb 1, 2021Oct 3, 2023Oct 28, 202444 United States, Ukraine
NCT04659161A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)PHASE3 COMPLETED 252Dec 16, 2020May 24, 2022Dec 12, 202322 United States
NCT03697252A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaPHASE2 COMPLETED 182Sep 18, 2018Sep 4, 2019Oct 26, 202012 United States
NCT02831231Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumPHASE1 COMPLETED 70Sep 7, 2016Oct 28, 2016Apr 19, 20171 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period
At Baseline and at Week 5 of the Double-Blind Period

PANSS Total Score is a clinical tool used to measure the severity of symptoms in individuals with schizophrenia. It includes 30 items divided into three subscales: Positive Symptoms (e.g., hallucinations, delusions) Negative Symptoms (e.g., social withdrawal, lack of motivation) General Psychopathology (e.g., anxiety, depression) Each item is rated from 1 (absent) to 7 (extreme), resulting in a total score range from 30 to 210. Higher PANSS Total Scores indicate more severe symptoms and worse clinical outcomes. Baseline is defined as last non-missing assessment prior to the first dose of study drug.

Incidence of treatment-emergent adverse events (TEAEs)
From initial dose to safety follow-up visit (54 weeks) or early termination
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
Baseline to Week 6

PANSS Total Score is a clinician administered measure of schizophrenia symptom severity used widely in antipsychotic research. It includes 30 items across 3 subscales: * Positive Symptoms (7 items) assessing excesses or distortions such as hallucinations, delusions, or grandiosity * Negative Symptoms (7 items) assessing diminished function such as social withdrawal or reduced motivation and * General Psychopathology (16 items) capturing broader symptoms like anxiety, depression, guilt, or cognitive impairment Each item is scored from 1 (absent) to 7 (extreme), producing a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. Baseline is defined as the last non missing PANSS Total Score before first dose. This endpoint evaluates change from Baseline to Week 6, with negative values indicating improvement.

Number of Participants With Treatment Emergent Adverse Events (TEAEs)
From time of consent to end of study (approximately 400 days)

TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
From baseline up to Week 5

The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of participants with schizophrenia and is widely used in the study of antipsychotic therapy. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility, and the negative symptoms in schizophrenia are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms. The PANSS Total Score is then the sum of the positive, negative, and general psychopathology symptom scores. Baseline is defined as the PANSS score at screening.

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
From first dose to end of study (Up to approximately 53 weeks)

TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Mean weekly maximum composite Visual Analogue Scale (VAS) score (nausea, diarrhea, sweating, salivation and vomiting combined) comparing xanomeline + placebo to xanomeline + trospium
7 days
Secondary Endpoints
Change From Baseline in Positive Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Negative Symptom Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
At Baseline and at Week 5 of the Double-Blind Period
Change From Baseline in Negative Marder Factor Score of the Positive and Negative Syndrome Scale (PANSS) at Week 5 of the Double-Blind Period
At Baseline and at Week 5 of the Double-Blind Period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelFACTORIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
KarXTEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Drug: KarXTEXPERIMENTAL -
Xanomeline plus placeboACTIVE_COMPARATORDrug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
Xanomeline plus trospiumEXPERIMENTALDrug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
Interventions
NameTypeDescription
Xanomeline and Trospium Chloride CapsulesDRUGOral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
PlaceboDRUGPlacebo Capsules
Placebo CapsulesDRUGPlacebo Capsules
xanomeline tartrateDRUGxanomeline tartrate, 75 mg capsule, TID
Trospium chlorideDRUGtrospium chloride, over encapsulated 20 mg tablet, BID
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites28

Inclusion Criteria: 1. Subject is Chinese national, aged 18 to 65 years, inclusive, at screening. 2. Subject is capable of providing written informed consent. 3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 and MINI. 4. Su...

Countries:ChinaUnited StatesBulgariaCzechiaIndiaJapanPolandRomaniaSerbiaUnited KingdomPuerto RicoUkraine
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMJun 5, 2026NCT05145413TRIAL_REMOVED: changed
MEDIUMJun 5, 2026NCT05145413TRIAL_REMOVED: changed
MEDIUMJun 5, 2026NCT05145413TRIAL_REMOVED: changed
MEDIUMJun 5, 2026NCT05145413TRIAL_REMOVED: changed
MEDIUMJun 5, 2026NCT05145413TRIAL_REMOVED: changed
MEDIUMJun 5, 2026NCT05145413TRIAL_REMOVED: changed
MEDIUMMay 26, 2026NCT05304767primaryCompletionDate: changed
LOWMay 24, 2026NCT05304767studyFirstPostDate: changed